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Background and aims: Increased pancreatitis associated protein (PAP) mRNA has been reported in active
inflammatory bowel disease (IBD). The aims of the current study were to characterise PAP production in
IBD and the effects of PAP on inflammation.
Patients and methods: Serum PAP levels were determined in healthy controls (n = 29), inflammatory
controls (n = 14), and IBD patients (n = 171). Ex vivo PAP secretion in intestinal tissue was measured in 56
IBD patients and 13 healthy controls. Cellular origin of PAP was determined by immunohistochemistry. The
effects of exogenous PAP on nuclear factor kB (NFkB) activation, proinflammatory cytokine production,
and endothelial adhesion molecule expression were also analysed ex vivo.
Results: Patients with active IBD had increased serum PAP levels compared with controls, and these levels
correlated with clinical and endoscopic disease severity. Ex vivo intestinal PAP synthesis was increased in
active IBD and correlated with endoscopic and histological severity of inflammatory lesions. PAP localised
to colonic Paneth cells. Incubation of mucosa from active Crohn’s disease with PAP dose dependently
reduced proinflammatory cytokines secretion. PAP prevented TNF-a induced NFkB activation in
monocytic, epithelial, and endothelial cells and reduced proinflammatory cytokine mRNA levels and
adhesion molecule expression.
Conclusions: PAP is synthesised by Paneth cells and is overexpressed in colonic tissue of active IBD. PAP
inhibits NFkB activation and downregulates cytokine production and adhesion molecule expression in
inflamed tissue. It may represent an anti-inflammatory mechanism and new therapeutic strategy in IBD.
P
ancreatitis associated protein I (PAP I) is a member of
the type III subclass of the REG gene family that was
first identified in rat pancreatic juice after experimental
pancreatitis.1 PAP I is also expressed in mice and humans, the
amino acid sequences of these proteins showing a high
degree of conservation.2 Human PAP is constitutively
expressed in the pancreas and small intestine.3 Increased
PAP mRNA has been documented in colonic mucosa from
patients with active inflammatory bowel disease (IBD)4–6 as
well as in experimental models of colitis.6 7
Although several functions have been proposed for PAP,
the physiological relevance of PAP upregulation in inflam-
matory diseases remains unknown. Recent observations
suggest that PAP may have a protective effect against
inflammatory damage in pancreatic8 9 and extrapancreatic10
inflammatory conditions.
In the current study, we characterised PAP synthesis in IBD,
examining its relationship with type of disease, ulcerative
colitis (UC) or Crohn’s disease (CD), and its severity, based on
clinical, endoscopic, and histological parameters. Given the
protective action of PAP against inflammatory damage
previously observed, we assessed whether PAP supplementa-
tion modulates signalling pathways in active IBD in ex vivo
studies, particularly whether it alters proinflammatory cyto-
kine synthesis in colonic inflamed mucosa from patients with
CD and UC. After observing that this was in fact the case, and
in order to gain a further mechanistic insight, we assessed
whether PAPmodulates activation of nuclear factor kB (NFkB)
in three different cell lines as models of the cell types that
orchestrate the chronic inflammation present in IBD—namely,
monocytes, epithelial cells, and endothelial cells. Finally, we
analysed if PAP could inhibit adhesion molecule expression in
stimulated endothelial cells.
METHODS
The study was approved by the ethics committee of the
Hospital Clı´nic de Barcelona, and all patients gave their
written informed consent before enrolment.
Analysis of serum PAP in IBD
PAP levels in serum were analysed in active or inactive IBD
patients (n=171), in healthy control subjects (n=29), and
in a group of patients with documented acute infectious
gastroenteritis (positive stool culture for Gram negative
bacteria) as intestinal inflammatory controls (n=14).
Patients or controls with previously known intestinal or
inflammatory diseases other than IBD, acute or chronic
pancreatitis, previous intestinal resection, or chronic renal
failure were excluded. In CD, clinical severity of the disease
was estimated using the CD activity index,11 and in UC with
the Lichtiger modified Truelove and Witts clinical activity
index.12 Biological markers of IBD activity (C reactive protein
(CRP) and erythrocyte sedimentation rate (ESR)) were also
determined.
Colonic disease extension was determined by colonoscopy
performed in all cases within six months before inclusion in
the study. In CD patients, small intestinal involvement was
assessed by a follow through performed within the same time
period. Location of CD was categorised into three subgroups:
ileal, colonic, and ileocolonic. Location of UC was categorised
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease;
UC, ulcerative colitis; PAP, pancreatitis associated protein; CRP, C
reactive protein; ESR, erythrocyte sedimentation rate; HUVEC, human
umbilical vein endothelial cells; IL, interleukin; IFN-c, interferon c; TNF-a,
tumour necrosis factor a; NFkB, nuclear factor kB; RT-PCR, reverse
transcription-polymerase chain reaction
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into two subgroups: distal, when lesions were confined to the
rectosigmoid region, and extensive.
Serum PAP was measured using a commercially available
ELISA kit (Dynabio SA, Marseille, France) and results are
expressed as ng of PAP per ml of serum.
Intestinal PAP synthesis in IBD
Intestinal PAP synthesis was analysed using ex vivo culture
of intestinal biopsy samples in 56 patients with IBD (41 with
UC and 15 with CD) and 13 healthy controls. Colonic biopsy
specimens were obtained from inflamed and/or non-inflamed
mucosa of patients with active or inactive IBD. Patients
receiving steroid treatment were excluded. Mucosal biopsies
were taken from control patients free of intestinal inflam-
matory disease who underwent colonoscopy for cancer
screening, in whom colonoscopy excluded the presence of
lesions. Endoscopic severity of UC was assessed following a
previously described scoring system.13 Evaluation of endo-
scopic severity in CD was referred to the area where biopsies
were taken and categorised as: inactive: no lesions; mild:
circumscribed aphthous lesions; moderate: superficial ulcers
,1 cm in length; and severe: deep ulcerations or ulcers
.1 cm in length. Biopsy specimens were examined blindly by
a single gastrointestinal pathologist (RM). Assessment of
histological severity of inflammation in biopsy samples was
performed using previously described grading scores for UC14
or CD.15
For measurement of PAP secretion by colonic tissue,
colonic biopsy samples weighing approximately 15–30 mg
were cultured at 37 C˚ with 5% CO2 for 24 hours. At the end of
the culture period, supernatants were recovered and stored at
280 C˚ for later analysis. Levels of PAP protein secreted were
analysed measuring PAP concentration in the supernatant by
ELISA (Dynabio SA). Results are expressed as ng PAP per mg
of tissue.
Localisation of PAP in intestinal biopsies
Cellular origin of PAP was determined using immunohisto-
chemistry. Colon or ileum paraffin sections from biopsy
samples of healthy subjects, patients with UC, and patients
with CD (n=3 per group) were stained with haematoxylin-
eosin, or immunostained with a rabbit polyclonal antibody
against human PAP (1/50). This antihuman PAP antibody
was generated by one of the investigators (JLI), as previously
described.16 Localisation of PAP in Paneth cells was con-
firmed by immunostaining for lysozyme (1/400; EnVision
System, Dako, Copenhagen, Denmark).
Effects of PAP on intestinal proinflammatory cytokine
production
Sets of four endoscopic biopsies from controls and patients
with active or inactive CD or UC were seeded on a well with
medium alone or supplemented with various concentrations
of PAP (25, 50, 500, or 2000 ng/ml). Biopsies were cultured at
37 C˚ with 5% CO2 for 24 hours. Then, supernatants were
recovered. Concentrations of interleukin 6 (IL-6), tumour
necrosis factor a (TNF-a), interferon c (IFN-c), interleukin
12p70 (IL-12p70), interleukin 18 (IL-18), and interleukin 8
(IL-8) in tissue culture supernatants were measured using
ELISA kits supplied by Diaclone (Besanc¸on, France). PAP
protein was obtained from human pancreatic juice collected
by endoscopic retrograde pancreatography and purified using
immunoaffinity chromatography, as previously described.10 16
Results are expressed as pg of cytokine per mg of tissue.
In order to determine whether PAP can penetrate into
cultured tissue, colonic biopsy samples from CD patients
(n=3), incubated for 24 hours with medium alone or
supplemented with 50 ng/ml PAP, were fixed with 4%
formaldehyde, and immunohistochemistry against PAP was
performed, as described previously.
Assessment of NFkB activation by
immunofluorescence in HT29 colonic cells
Human HT29 epithelial colonic cell line was cultured at 37 C˚
with 5% CO2. Cells were preincubated for one hour with
various doses of PAP (50, 500, or 1000 ng/ml) and challenged
with 10 ng/ml of TNF-a (Sigma, St Louis, Missouri, USA) for
30 minutes at 37 C˚. Thereafter, cells were incubated with a
rabbit polyclonal anti-NFkB p65 (C-20) antibody (Santa Cruz
Biotechnology, Santa Cruz, California, USA) for one hour,
followed by incubation with a goat antirabbit FITC anti-
body (Santa Cruz Biotechnology) for one hour in the dark.
After washing, slides were mounted for fluorescence
microscopy.
Quantification of PAP effects on NFkB activation in
different cell types
Human promonocytic THP-1 cells as model of immune cells,
human HT29 epithelial colonic cells, and human umbilical
vein endothelial cells (HUVECs) were used. All cell lines were
maintained at 37 C˚ with 5% CO2. Cells were preincubated for
one hour with various doses of PAP (50, 100, 500, or 1000 ng/
ml) and activated or not with 10 ng/ml TNF-a for 30 minutes
at 37 C˚. Then, nuclear extracts were obtained using a nuclear
extract kit from Active Motif (Rixensart, Belgium) and
activation of NFkB was measured with a commercial ELISA
kit (TransAM; Active Motif). Results are expressed as fold
induction of NFkB after TNF-a stimulation.
Assessment of PAP effects on stimulated TNF-a
expression in HT29 cells
HT29 cells maintained at 37 C˚ with 5% CO2 were preincu-
bated for one hour with various doses of PAP (50, 100, 500, or
1000 ng/ml) and stimulated or not with 10 ng/ml TNF-a for
30 minutes at 37 C˚. Then, total RNA was obtained to evaluate
changes in TNF-a mRNA expression using quantitative real
time reverse transcription-polymerase chain reaction (RT-
PCR) analysis on a LightCycler detection system (Roche
Applied Science, Basel, Switzerland). Expression levels of
TBP gene (encoding the TATA binding protein) were used as
an internal control. First strand cDNA was synthesised from
2 mg of total RNA using random hexamers and expanded by
reverse transcriptase according to the manufacturer’s instruc-
tions (Roche Applied Science), subsequently diluted 1:10
with water, and stored at 220 C˚ until use. TNF-a and TBP
PCR products were detected using the Quantitect Probe PCR
kit (Qiagen Operon, Cologne, Germany), following the
manufacturer’s instructions, using the dual fluorescent
Taqman probes (Qiagen Operon) 59-FAM-TAG CCC ATG
TTG TAG CAA ACC CTC AAG CT-TAMRA-39 (position 435)
and 59-FAM-TCC CAA GCG GTT TGC TGC GGT A-TAMRA-39
(position 811), respectively. The following primers were used:
TBP forward (position 791) 59-GCC CGA AAC GCC GAA TAT
A-39 and TBP reverse 59-CGT GGC TCT CTT ATC CTC ATG A-
39 (position 855); TNF-a forward 59- TCT TCT CGA ACC CCG
AGT GA-39 (position 407) and TNF-a reverse 59- CCT CTG
ATG GCA CCA CCA G-39 (position 557). Quantitative real
time RT-PCR was performed in a total volume of 20 ml
containing 16 amplification buffer and 5 ml cDNA template.
Samples were heated for 15 minutes at 95 C˚ and amplified
for 45 cycles (denaturation at 95 C˚ for 10 seconds, annealing
and elongation at 60 C˚ for 60 seconds with a transition rate
of 20 C˚/s). All samples were analysed in duplicate. Data
evaluation was performed using the LightCycler data analysis
software (version 3.5).
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Effects of PAP on adhesion molecule expression in
endothelial cells
HUVECs were incubated for 20 hours at 37 C˚ with 5% CO2
and various concentrations of PAP (25, 50, 100, 250, or
1000 ng/ml) in the presence or absence of 10 ng/ml TNF-a,
washed, and incubated for 45 minutes with an anti-
E-selectin antibody (68-5H11), an anti-ICAM-1 antibody
(HA58), or an anti-VCAM-1 antibody (51-10C9). Antibodies
were purchased from BD Pharmingen (Heidelberg,
Germany). After several washes, cells were incubated with
a horseradish peroxidase conjugated secondary antimouse
IgG antibody (Caltag, Burlingame, California, USA) for
30 minutes and a developing solution of OPD (Sigma).
Absorbance was read at a wavelength of 450 nm. Results are
expressed as per cent of OD450 nm reduction versus OD450 nm
of TNF-a activated cells.
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Figure 1 (A) Serum pancreatitis associated protein (PAP) levels in inflammatory bowel disease (IBD) patients with disease of diverse severity. Inactive
Crohn’s disease (CD, n = 63) or ulcerative colitis (UC, n = 34) patients had higher PAP levels than healthy controls (n = 29) or inflammatory controls
(infectious diarrhoea, n =14). In IBD patients, PAP levels increased in parallel with disease severity, categorised as: mild (CD n=23, UC n=14),
moderate (CD n =18, UC n =9), or severe (CD n=4, UC n =6). *p,0.05 versus healthy controls and inflammatory controls; p,0.05 versus inactive
disease; `p,0.05 versus mild disease; 1p,0.05 versus moderate disease; p,0.05 versus severe UC. Correlation of serum PAP levels with CD
activity index (CDAI) in CD patients (B) and with the Lichtiger modified Truelove and Witts clinical activity index in UC patients (C). Correlation of serum
PAP levels with serum C reactive protein (CRP) levels in CD (D) and UC (E) patients. Correlation of serum PAP levels with erythrocyte sedimentation rate
(ESR) in CD (F) and UC (G) patients. (H) Serum PAP levels in CD patients according to location of intestinal lesions: ileal (n = 26), ileocolonic (n = 24), or
colonic (n = 20). (I) Serum PAP levels in UC patients according to disease extension: distal (n = 21) or extensive (n = 42). Results are expressed as ng
PAP/ml serum.
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Statistical analysis
Data were analysed using ANOVA with Bonferroni post hoc
test or the non-parametric Kruskal-Wallis test with Dunn’s
post hoc test for multiple group comparisons, when appro-
priate. Repeated measures for the same patient were analysed
using the Student’s paired t test. Correlation Z test was used
to establish correlations between two quantitative variables.
Values are expressed as mean (SEM). Statistical significance
was set at p,0.05.
RESULTS
Study 1: analysis of serum PAP in IBD
The presence of chronic intestinal inflammation was asso-
ciated with increased production of PAP, as estimated from
serum levels of the protein. In comparison with healthy
controls (n=29), increased PAP levels in serum were already
detected in patients with clinically inactive CD (n=63) or UC
(n=34), and were further increased in those with active IBD
(CD n=45; UC n=29), in association with severity of
disease, as measured by the corresponding clinical activity
indexes (fig 1A). Serum PAP levels had a positive and
significant correlation with clinical activity indexes in both
CD (r=0.70, p,0.0001) (fig 1B) and UC (r=0.44, p,0.001)
(fig 1C). PAP levels also correlated positively and significantly
with serum CRP levels (CD r=0.28, p,0.02; UC r=0.45,
p,0.001) and with ESR (CD r=0.27, p,0.01; UC r=0.45,
p,0.001), although these correlations were weak. In con-
trast, serum levels of PAP in a group of patients with acute
intestinal inflammation due to intestinal infection (n=14)
were identical to those of healthy control subjects (fig 1A).
CRP values of this group of inflammatory controls (4.26
(1.78)) were not different from those of IBD patients with
active disease (3.89 (0.66)).
In CD, serum PAP levels were not influenced by location of
inflammatory lesions; similar values were observed when
patients with ileal, ileocolonic, or colonic lesions of similar
clinical severity were compared (fig 1H). In UC, serum PAP
levels were also not related to disease extension; similar
levels were found in distal and extensive colitis of similar
clinical severity (fig 1I). When patients with CD and UC were
stratified according to disease severity, PAP levels were
similar in both diseases in mild and moderate cases but were
significantly higher in severe CD compared with severe UC.
Study 2: characterisation of intestinal PAP production
in IBD
Ex vivo analysis of PAP secretion in colonic tissue
from IBD patients
PAP secretion was significantly increased in the mucosa of
patients with active CD (n=10) and UC (n=36) compared
with mucosa from patients with inactive disease (CD n=5;
UC n=5) or control patients (n=13). In patients with IBD,
ex vivo PAP secretion paralleled the severity of colonic
inflammation assessed by endoscopy (fig 2A). Levels of
secreted PAP also correlated with histological severity of
intestinal inflammation in both CD (r=0.870; p=0.0004)
(fig 2B) and UC (r=0.616; p=0.0001) (fig 2C). When levels
of secreted PAP of healthy and inflamed colonic mucosa from
the same patient were compared (n=10), low basal levels of
PAP (0.01 (0.01) ng/mg tissue) secreted by the healthy tissue
contrasted with the significantly higher levels observed in
inflamed tissue (1.94 (0.21) ng/mg tissue; p,0.01) (fig 2D),
indicating that increased PAP secretion is restricted to areas
involved by the chronic inflammatory process.
Paneth cells express PAP in active IBD
Immunostaining of human colonic mucosa from healthy
controls did not reveal any positive signal for PAP. In
contrast, positive staining for PAP protein in CD and UC
colonic mucosa was clearly detected in epithelial cells located
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Figure 2 Ex vivo pancreatitis
associated protein (PAP) production in
intestinal tissue of patients with
inflammatory bowel disease (IBD) and
controls. (A) PAP secretion paralleled
the endoscopic severity of lesions in
Crohn’s disease (CD, n =15) and
ulcerative colitis (UC, n = 41). *p,0.05
versus mild disease; p,0.05 versus
inactive disease. Correlation of PAP
secretion levels with the histological
index in CD (B) and UC (C).
(D) Samples of healthy and inflamed
intestinal mucosa from 10 IBD patients
were assayed in parallel. Inflamed
mucosa secreted significantly more PAP
than healthy tissue (paired t test,
p,0.01).
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at the bottom of crypts (fig 3E, F). Haematoxylin-eosin
staining of colonic serial sections indicated that PAP
expressing cells exhibited a characteristic morphology of
Paneth cells, including the presence of acidophilic granules.
Lysozyme staining confirmed localisation of PAP to Paneth
cells in UC and also in CD (fig 3C, D).
Study 3: effects of PAP on intestinal inflammation
Proinflammatory cytokine secretion in CD and UC
biopsies
Active CD is characterised by increased production of several
proinflammatory cytokines such as TNF-a , IL-6, IL-8,17–19
IFN-c,20 IL-1221 and IL-18.22 Secretion of all of these
proinflammatory cytokines by the inflamed mucosa from
patients with CD (n=6) was significantly reduced on
incubation with 50 ng/ml PAP to a variable extend
(19–55%), with the most marked reductions observed with
IFN-c, TNF-a, and IL-6 (fig 4A). Higher concentrations of
PAP (500 or 2000 ng/ml) did not induce further inhibition of
cytokine secretion, whereas incubation with 25 ng/ml had a
significantly weaker inhibiting effect, as shown in fig 4B. PAP
had no significant effects on cytokine secretion by colonic
mucosa from patients with inactive CD (n=4) or from
healthy controls (n=4) in which baseline levels of cytokine
secretion were low (data not shown). To rule out possible
interference of PAP with the cytokine ELISA assays, PAP was
added just before the cytokine assays to the culture medium
of tissue samples incubated without PAP. Addition of PAP to
the assay medium did not alter cytokine levels measured by
ELISA.
Figure 3 Pancreatitis associated
protein (PAP) in the colon of Crohn’s
disease (CD) and ulcerative colitis (UC)
patients is synthesised in Paneth cells.
Immunohistochemistry of consecutive
colon paraffin sections are shown.
Representative images from a UC
patient have been chosen.
Haematoxylin-eosin staining
demonstrated the presence of
metaplastic Paneth cells in the
descending colon (A, 2006; B, 6006).
Immunostaining for lysozyme precisely
identified Paneth cells at the base of
crypts (C, 2006; D, 6006).
Immunostaining for PAP is seen in
metaplastic Paneth cells (E, 2006; F,
6006). No staining was observed in
sections incubated without primary
antibody (data not shown). All sections
were counterstained with haematoxylin.
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In contrast with the uniform response observed in CD,
incubation of inflamed colonic mucosa from patients with UC
in the presence of PAP showed variable results. Globally,
incubation of inflamed colonic mucosa with PAP 50 ng/ml
did not significantly modify secretion of the proinflammatory
cytokines relative to samples incubated in the absence of
PAP: TNF-a (217.3 (23.4); n=8), IL-6 (+3.3 (22.8); n=8),
INF-c (2-43.6 (19.7); n=4), or IL-8 (222.7 (19.3); n=4).
Nevertheless, 50% of patients studied responded with a
decrease in the production of these cytokines after incubation
with PAP. Higher concentrations of PAP (500 or 2000 ng/ml)
did not induce further inhibition or increase the proportion of
responses (data not shown). We did not analyse IL-18 or
IL-12 secretion in UC biopsies because levels of these
cytokines in tissue culture supernatants were not increased
during inflammation, a finding in keeping with previous
observations.21 22
To determine whether exogenous PAP can penetrate into
cultured colonic tissue, biopsies incubated in the presence or
absence of this protein were immunostained for PAP. As
shown in fig 5, immunostaining was detected in the
cytoplasm of epithelial cells of the samples incubated with
this protein whereas in biopsies incubated with medium
alone the signal was only present in Paneth cells, as
mentioned above. This result indicates that epithelial cells
are the main target for PAP and that these cells are able to
internalise it.
NFkB activation in different cell types
Expression of cytokines that are downregulated on incuba-
tion of inflamed CD tissue with PAP is in part regulated by
NFkB.23–28 We hypothesised that inhibition of NFkB activa-
tion might be one of the mechanisms mediating the anti-
inflammatory effect of PAP.
Initially, immunofluorescence studies were used to moni-
tor the effects of PAP on NFkB activation in the colonic
epithelial cell line HT29 challenged with TNF-a. In non-
stimulated cells, NFkB p65 staining was detected only in the
cytoplasm (fig 6A). Stimulation of these cells with 10 ng/ml
TNF-a induced translocation of NFkB p65 to the nucleus
(fig 6B). Incubation of stimulated cells with 50, 500, or
1000 ng/ml PAP inhibited translocation of NFkB p65 in most
cells (fig 6C, D, E), as staining remained predominantly
cytoplasmic. Inhibition was stronger with 500 ng/ml PAP
than with 50 ng/ml but did not further increase when a
concentration of 1000 ng/ml was used. Incubation of non-
stimulated cells with PAP did not result in activation of NFkB
(fig 6F, G, H).
To confirm the inhibitory ability of PAP on TNF-a induced
NFkB activation, and to explore its differential effects in
different cell types, we used a quantitative NFkB activation
assay (TransAM). Monocytes, epithelial cells, and endothelial
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Figure 4 Reduction of cytokine secretion from mucosa samples
incubated with pancreatitis associated protein (PAP). (A) Colonic
biopsies from inflamed mucosa of patients with Crohn’s disease (CD,
n = 6) were cultured for 24 hours in medium alone or with 50 ng/ml
PAP, and concentrations of proinflammatory cytokines in culture
supernatants were measured by ELISA. Secretion of the following
cytokines was monitored: tumour necrosis factor a (TNF-a), interleukin
(IL)-6, interferon c (IFN-c), IL-18, IL-12, and IL-8. (B) Dose-response
relationship between PAP (25, 50, 500, 2000 ng/ml) supplemented
medium and TNF-a secretion in the same biopsies as above. Results are
expressed as per cent changes in cytokine secretion in tissue samples
incubated with PAP relative to samples incubated with medium alone.
*p,0.05 for each cytokine, paired t test.
Figure 5 Presence of pancreatitis associated protein (PAP) in epithelial
cells of colonic biopsies incubated with this protein. Immunohisto-
chemistry for PAP in colonic sections from a patient with Crohn’s disease
(CD) incubated for 24 hours with medium alone (A) or with 50 ng/ml
PAP (B). (A) In the absence of PAP in the medium, immunostaining for
PAP was only found in Paneth cells at the base of the crypts; no signal
was found in other epithelial cells (4006). (B) In tissue samples incubated
in the presence of exogenous PAP, the protein was diffusely identified in
the cytoplasm of all epithelial cells (6006). All sections were
counterstained with haematoxylin.
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cells have been implicated in the pathogenesis of IBD,29 and
these cell types show activation of NFkB in inflamed
intestinal mucosa.30 31 To investigate which cell types may
be affected by PAP, NFkB activation was measured in
stimulated human THP-1 monocytic cells, HT29 epithelial
cells, and HUVECs. As shown in fig 7, PAP inhibited TNF-a
induced NFkB activation in all three cell types, in a dose
dependent manner, with THP-1 cells showing the highest
degree of inhibition. Addition of 100–500 ng/ml PAP to the
culture medium in non-stimulated cells did not alter NFkB
activation.
Effects of PAP on stimulated TNF-a transcription
To test the possible link between the effects of PAP on NFkB
activation and cytokine production in cell lines, we mon-
itored expression of TNF-a mRNA in stimulated HT29 cells
after incubation with PAP by real time RT-PCR. As shown in
fig 8, addition of PAP to the culture medium reduced TNF-a
induced transcript levels in a dose dependent manner,
confirming the inhibitory action of PAP on proinflammatory
cytokine production through transcription regulation.
Endothelial adhesion molecule expression
Endothelial cells are activated in active IBD32 33 and this
activation is accompanied by an increase in adhesion
molecule expression. Endothelial expression of E-selectin,
ICAM-1, and VCAM-1 is strongly induced by TNF-a and is
dependent on NFkB activation.34 We explored whether PAP
could also affect TNF-a induced adhesion molecule expres-
sion in HUVECs. Indeed, PAP significantly inhibited TNF-a
induced adhesion molecule upregulation in a dose dependent
manner. E-selectin upregulation was most sensitive to the
effects of PAP whereas ICAM-1 and VCAM-1 upregulation
were only affected by the highest doses of PAP (fig 9).
DISCUSSION
In this study, we have shown that serum PAP levels were
increased in patients with IBD relative to healthy controls,
and this increase seemed to be specific for chronic intestinal
inflammation as serum PAP was not increased in patients
with intestinal inflammation in the context of infectious
diarrhoea. The concept that intestinal PAP production is
elevated in active IBD had already been put forward in
studies based on measurement of PAP mRNA in intestinal
samples.4–6 In the current study, we explored whether disease
type, location, or severity influenced PAP production. We
provided evidence that in both CD and UC, serum PAP levels
parallel disease severity. Nevertheless, patients with inactive
disease had still higher serum PAP levels than those of
control healthy subjects. The increase in PAP production in
active disease bore no relationship to type or location of
disease. This observation is at odds with a recent study
involving CD patients which found increased PAP levels only
in those with ileal disease.35 Our results, including a
significant number of CD patients with disease limited to
the colon and, even more convincingly, the observation of
increased PAP levels in patients with UC, clearly indicates
that production of this protein is also increased in the
presence of inflammation limited to the colon. The notion
that PAP production is increased in relation to the severity of
intestinal inflammation was confirmed in the ex vivo studies
measuring PAP production in inflamed intestinal tissue, in
which highly significant correlations were found between
histological and endoscopic severity of intestinal inflamma-
tion and PAP liberation to the culture medium.
Increased PAP production in both ileal and colonic disease
is probably related to hyperplasia and metaplasia of Paneth
cells. In the immunohistochemistry study performed in tissue
samples obtained from patients with active IBD, we observed
that PAP protein localised in Paneth cells in ileal and also in
Figure 6 Effect of pancreatitis associated protein (PAP) on nuclear translocation of nuclear factor kB (NFkB) in colonic epithelial cells. The intracellular
location of NFkB p65 was determined in HT29 cells by immunofluorescence using an anti-NFkB p65 antibody with FITC labelling. In non-stimulated
cells incubated with medium alone, staining was cytoplasmic (A). (B) Cells stimulated with 10 ng/ml tumour necrosis factor a (TNF-a) showed diffuse
immunostaining, indicating that NFkB had translocated from the cytoplasm to the nucleus. (C) Stimulated cells in the presence of 50 ng/ml PAP
maintained predominantly cytoplasmic NFkB immunostaining, indicating inhibition of NFkB translocation. Incubation of stimulated cells with
500 ng/ml (D) or 1000 ng/ml (E) PAP resulted in nearly complete restriction of immunostaining to the cytoplasm, indicating stronger inhibition of
NFkB translocation. In cells incubated with PAP 50 ng/ml (F), 500 ng/ml (G), and 1000 ng/ml (H) in the absence of TNF-a, immunostaining of NFkB
was restricted to the cytoplasm. All preparations were blindly examined in a fluorescence microscope with 10006.
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colonic tissue. This observation is in keeping with a recent
study6 and may explain the marginal but significant increase
in serum PAP in inactive IBD as hyperplasia and metaplasia
of Paneth cells is maintained during periods of quiescent
disease.
The role that increased PAP production may have on the
course of intestinal inflammation is currently unknown. Here
we provide evidence that exogenous PAP supplementation
can penetrate into intestinal tissue, specifically into epithelial
cells, and oppose the inflammatory process that takes place in
IBD. We demonstrated that secretion of proinflammatory
cytokines by colonic tissue of patients with active CD was
inhibited by addition of PAP, and that downregulation of
cytokine production occurred through a mechanism invol-
ving inhibition of NFkB activation. PAP inhibited TNF-a
induced NFkB activation in three cell types that participate in
the initiation and perpetuation of intestinal inflammation—
that is, monocytes, epithelial cells, and endothelial cells.29
Increased expression of adhesion molecules is another
important factor involved in the pathogenesis of IBD.36 We
asked whether PAP could directly affect these determinants
of leucocyte recruitment by monitoring expression of
E-selectin, ICAM-1, and VCAM-1, as these molecules are
upregulated through a NFkB dependent mechanism.34 TNF-a
induced expression of these adhesion molecules was sig-
nificantly reduced when cells were challenged in the presence
of PAP. Hence PAP could also counteract the inflammatory
response by inhibiting leucocyte recruitment into the intes-
tine. Unfortunately, we could not directly assess the anti-
inflammatory role of endogenous PAP due to the lack of
blocking antibodies and absence of knockout animal models.
In the current study, we observed that supplementation
with exogenous PAP did not have the same anti-inflamma-
tory effect in the inflamed mucosa of CD and UC. We
observed a significant and consistent reduction of cytokine
production in all samples of inflamed tissue from CD
patients, whereas only 50% of patients with UC responded
with a reduction in cytokine production, and this decrease
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Figure 7 Effects of pancreatitis associated protein (PAP) on nuclear
factor kB (NFkB) activation in THP-1 cells (A), HT29 cells (B), and human
umbilical vein endothelial cells (C). Cells were preincubated for one hour
with increasing PAP concentrations (0, 50, 100, 500, or 1000 ng/ml)
and stimulated with 10 ng/ml tumour necrosis factor a (TNF-a) for
30 minutes. Nuclear extracts were obtained, and activated NFkB was
measured using an oligonucleotide based specific ELISA (TransAM).
NFkB activation in TNF-a stimulated cells was significantly reduced in a
dose dependent manner by incubation with PAP. Results are expressed
as NFkB-fold induction Experiments were performed in quadruplicate
and all results are expressed as mean (SEM). *p,0.05 versus previous
PAP dose; p,0.05 versus TNF-a (2) PAP 0 ng/ml.
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Figure 8 Tumour necrosis factor a (TNF-a) mRNA expression
normalised to endogenous control TBP gene. HT29 cells were
preincubated for one hour with increasing pancreatitis associated
protein (PAP) concentrations (0, 50, 100, 500, or 1000 ng/ml) and
stimulated with 10 ng/ml TNF-a for 30 minutes. Total RNA was
extracted and TNF-a mRNA expression was quantified by quantitative
real time reverse transcription-polymerase chain reaction. TNF-a
expression in stimulated cells was significantly reduced in a dose
dependent manner by incubation with PAP. Results are shown as
percentage relative to TNF-a expression in control cells (100%) given as
mean (SEM) of four different experiments. *p,0.05 versus previous PAP
dose; p,0.05 versus control (TNF-a (2) PAP 0 ng/ml).
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did not reach statistical significance when we examined the
UC group as a whole. Such a difference could be attributable
to the fact that immune cell activation patterns present in CD
and UC are different. Activation of immune response in CD is
of the Th1-type, with increased production of TNF-a, IL-12,
IFN-c, and IL-18, and a clinical response to immunoblockade
of some of these cytokines such as TNF-a or IL-12,37 whereas
the pattern of immune cell activation in UC is more complex.
Discrepancies between the response of UC and CD to various
forms of treatment, such as ciclosporin12 38 or methotrex-
ate,39 40 has been previously documented in clinical controlled
trials. Thus it is conceivable that if blockade of cytokines
involved in the Th1-type response is a key element in
reducing activation of the immune system by PAP in CD, this
may not have the same effect in UC.
In conclusion, this study demonstrates that PAP synthesis
is increased in IBD, to an extent that parallels the severity of
intestinal inflammation. This increment is probably related to
hyperplasia/metaplasia of Paneth cells, which is in keeping
with the notion that these cells exert mostly a protective
function in intestinal homeostasis. PAP secreted by these
cells may dampen the inflammatory damage by affecting
diverse components of the inflammatory response, including
cytokine production, adhesion molecule expression, and
activation of NFkB. Although the finding of increased levels
of a potential anti-inflammatory factor paralleling disease
severity may be puzzling, it may reflect activation of
regulatory functions to limit tissue damage, as has been
described for other molecules that downregulate various
elements of the inflammatory cascade, such as IL-10 and
IFN-c.41 42 In that regard, increased PAP levels in inactive
disease may also have a role in maintaining a balance
between anti- and proinflammatory factors in an inflamma-
tion prone intestine. If PAP was eventually shown to be
effective in the treatment of human CD, the use of a small
human recombinant protein may have numerous advantages
over antibody based therapies in terms of tolerance and
immunogenicity.
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